SFX by Ex Libris Inc.

Title:	Integrative genomics identifies LMO1 as a neuroblastoma oncogene
Source:	Nature [0028-0836] Wang, K yr:2010

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Mossé, Andrew M. "Identification of ALK as a major familial neuroblastoma predisposition gene." Nature 455.7215 (2008): 930-935.
description	2.	Udayakumar, D. "Epha2 is a critical oncogene in melanoma." Oncogene 30.50 (2011): 4921-9.
description	3.	Langfelder, P. "WGCNA: an R package for weighted correlation network analysis." BMC bioinformatics 9.1 (2008): 559-559.
description	4.	Loose, M. "Global genetic regulatory networks controlling hematopoietic cell fates." Current opinion in hematology 13.4 (2006): 229-36.
description	5.	Bishop, J M M. "Targeted expression of MYCN causes neuroblastoma in transgenic mice." The EMBO journal 16.11 (1997): 2985-95.
description	6.	Ogawa, Y. "Oncogenic mutations of ALK kinase in neuroblastoma." Nature 455.7215 (2008): 971-4.
description	7.	George, R. "Activating mutations in ALK provide a therapeutic target in neuroblastoma." Nature 455.7215 (2008): 975-978.
description	8.	Zhang, B. "A General Framework for Weighted Gene Co-Expression Network Analysis." Statistical applications in genetics and molecular biology 4.1 (2005): 1128-43.
description	9.	Van Maerken, T. "Small-molecule MDM2 antagonists as a new therapy concept for neuroblastoma." Cancer research 66.19 (2006): 9646-55.
description	10.	Mikkola, Hanna K A A. "Transcriptional activators, repressors, and epigenetic modifiers controlling hematopoietic stem cell development." Pediatric research 59.4 (2006): 33-9.
description	11.	Cheli, Y. "Mitf is the key molecular switch between mouse or human melanoma initiating cells and their differentiated progeny.(ORIGINAL ARTICLE)(Report)." Oncogene 30.20 (2011): 2307-.
description	12.	Easty, David J. "Receptor tyrosine kinases and their activation in melanoma." Pigment cell & melanoma research 24.3 (2011): 446-461.
description	13.	Walker-Daniels, J. "Overexpression of the EphA2 tyrosine kinase in prostate cancer." The Prostate 41.4 (1999): 275-80.
description	14.	Bogan, C. "Loss of EphA2 receptor tyrosine kinase reduces ApcMin/+ tumorigenesis." International journal of cancer 124.6 (2009): 1366-1371.
description	15.	Bell, E. "MYCN oncoprotein targets and their therapeutic potential." Cancer Letters 293.2 (2010): 144-157.
description	16.	Carén,, Helena, H. "High-risk neuroblastoma tumors with 11 q-deletion display a poor prognostic, chromosome instability phenotype with later onset." Proceedings of the National Academy of Sciences of the United States of America 107.9 (2010): 4323-4328.
description	17.	Murad, Yanal M. "CpG oligodeoxynucleotides as TLR9 agonists: therapeutic applications in cancer." BioDrugs 23.6 (2009): 361-375.
description	18.	Presson, A. "Integrated Weighted Gene Co-expression Network Analysis with an Application to Chronic Fatigue Syndrome." BMC systems biology 2.1 (2009): 95-95.
description	19.	BRODEUR, G. "AMPLIFICATION OF N-MYC IN UNTREATED HUMAN NEUROBLASTOMAS CORRELATES WITH ADVANCED DISEASE STAGE." Science 224.4653 (1984): 1121-1124.
description	20.	Leek, Jeffrey T T. "Capturing heterogeneity in gene expression studies by surrogate variable analysis." PLoS Genetics 3.9 (2007): 1724-35.